A citation-based method for searching scientific literature

Elena Ardini, Maria Menichincheri, Patrizia Banfi, Roberta Bosotti, Cristina De Ponti, Romana Pulci, Dario Ballinari, Marina Ciomei, Gemma Texido, Anna Degrassi, Nilla Avanzi, Nadia Amboldi, Maria Beatrice Saccardo, Daniele Casero, Paolo Orsini, Tiziano Bandiera, Luca Mologni, David Anderson, Ge Wei, Jason Harris, Jean-Michel Vernier, Gang Li, Eduard Felder, Daniele Donati, Antonella Isacchi, Enrico Pesenti, Paola Magnaghi, Arturo Galvani. Mol Cancer Ther 2016
Times Cited: 183







List of co-cited articles
1033 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Alexander Drilon, Salvatore Siena, Sai-Hong Ignatius Ou, Manish Patel, Myung Ju Ahn, Jeeyun Lee, Todd M Bauer, Anna F Farago, Jennifer J Wheler, Stephen V Liu,[...]. Cancer Discov 2017
473
48

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Alexander Drilon, Theodore W Laetsch, Shivaani Kummar, Steven G DuBois, Ulrik N Lassen, George D Demetri, Michael Nathenson, Robert C Doebele, Anna F Farago, Alberto S Pappo,[...]. N Engl J Med 2018
44

Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
Maria Menichincheri, Elena Ardini, Paola Magnaghi, Nilla Avanzi, Patrizia Banfi, Roberto Bossi, Laura Buffa, Giulia Canevari, Lucio Ceriani, Maristella Colombo,[...]. J Med Chem 2016
145
38

NTRK fusion-positive cancers and TRK inhibitor therapy.
Emiliano Cocco, Maurizio Scaltriti, Alexander Drilon. Nat Rev Clin Oncol 2018
609
37

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.
Alexander Drilon, Sai-Hong Ignatius Ou, Byoung Chul Cho, Dong-Wan Kim, Jeeyun Lee, Jessica J Lin, Viola W Zhu, Myung-Ju Ahn, D Ross Camidge, Judy Nguyen,[...]. Cancer Discov 2018
208
35

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.
Alexander Drilon, Ramamoorthy Nagasubramanian, James F Blake, Nora Ku, Brian B Tuch, Kevin Ebata, Steve Smith, Veronique Lauriault, Gabrielle R Kolakowski, Barbara J Brandhuber,[...]. Cancer Discov 2017
232
29

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Robert C Doebele, Alexander Drilon, Luis Paz-Ares, Salvatore Siena, Alice T Shaw, Anna F Farago, Collin M Blakely, Takashi Seto, Byung Chul Cho, Diego Tosi,[...]. Lancet Oncol 2020
535
29

Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.
Mariangela Russo, Sandra Misale, Ge Wei, Giulia Siravegna, Giovanni Crisafulli, Luca Lazzari, Giorgio Corti, Giuseppe Rospo, Luca Novara, Benedetta Mussolin,[...]. Cancer Discov 2016
207
25

TRKing down an old oncogene in a new era of targeted therapy.
Aria Vaishnavi, Anh T Le, Robert C Doebele. Cancer Discov 2015
370
25

Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Alice T Shaw, Sai-Hong I Ou, Yung-Jue Bang, D Ross Camidge, Benjamin J Solomon, Ravi Salgia, Gregory J Riely, Marileila Varella-Garcia, Geoffrey I Shapiro, Daniel B Costa,[...]. N Engl J Med 2014
21

What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).
A Drilon, G Li, S Dogan, M Gounder, R Shen, M Arcila, L Wang, D M Hyman, J Hechtman, G Wei,[...]. Ann Oncol 2016
196
21

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Alexander Drilon, Salvatore Siena, Rafal Dziadziuszko, Fabrice Barlesi, Matthew G Krebs, Alice T Shaw, Filippo de Braud, Christian Rolfo, Myung-Ju Ahn, Jürgen Wolf,[...]. Lancet Oncol 2020
188
21

NTRK gene fusions as novel targets of cancer therapy across multiple tumour types.
Alessio Amatu, Andrea Sartore-Bianchi, Salvatore Siena. ESMO Open 2016
308
20

Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Theodore W Laetsch, Steven G DuBois, Leo Mascarenhas, Brian Turpin, Noah Federman, Catherine M Albert, Ramamoorthy Nagasubramanian, Jessica L Davis, Erin Rudzinski, Angela M Feraco,[...]. Lancet Oncol 2018
286
19

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.
A Vaishnavi, M Capelletti, A T Le, S Kako, M Butaney, D Ercan, S Mahale, K D Davies, D L Aisner, A B Pilling,[...]. Nat Med 2013
411
18

ROS1 rearrangements define a unique molecular class of lung cancers.
Kristin Bergethon, Alice T Shaw, Sai-Hong Ignatius Ou, Ryohei Katayama, Christine M Lovly, Nerina T McDonald, Pierre P Massion, Christina Siwak-Tapp, Adriana Gonzalez, Rong Fang,[...]. J Clin Oncol 2012
17

Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer.
Justin F Gainor, Diane Tseng, Satoshi Yoda, Ibiayi Dagogo-Jack, Luc Friboulet, Jessica J Lin, Harper G Hubbeling, Leila Dardaei, Anna F Farago, Katherine R Schultz,[...]. JCO Precis Oncol 2017
148
17

An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.
Robert C Doebele, Lara E Davis, Aria Vaishnavi, Anh T Le, Adriana Estrada-Bernal, Stephen Keysar, Antonio Jimeno, Marileila Varella-Garcia, Dara L Aisner, Yali Li,[...]. Cancer Discov 2015
255
17


Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors.
Dazhi Liu, Michael Offin, Stephen Harnicar, Bob T Li, Alexander Drilon. Ther Clin Risk Manag 2018
55
29

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.
Ryohei Katayama, Bo Gong, Noriko Togashi, Masaya Miyamoto, Masaki Kiga, Shiho Iwasaki, Yasuki Kamai, Yuichi Tominaga, Yasuyuki Takeda, Yoshiko Kagoshima,[...]. Nat Commun 2019
62
25

The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib.
Tejas Patil, Derek E Smith, Paul A Bunn, Dara L Aisner, Anh T Le, Mark Hancock, William T Purcell, Daniel W Bowles, D Ross Camidge, Robert C Doebele. J Thorac Oncol 2018
77
19

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.
A T Shaw, G J Riely, Y-J Bang, D-W Kim, D R Camidge, B J Solomon, M Varella-Garcia, A J Iafrate, G I Shapiro, T Usari,[...]. Ann Oncol 2019
169
15

Molecular characterization of cancers with NTRK gene fusions.
Zoran Gatalica, Joanne Xiu, Jeffrey Swensen, Semir Vranic. Mod Pathol 2019
245
14

Entrectinib: a potent new TRK, ROS1, and ALK inhibitor.
Christian Rolfo, Rossana Ruiz, Elisa Giovannetti, Ignacio Gil-Bazo, Antonio Russo, Francesco Passiglia, Marco Giallombardo, Marc Peeters, Luis Raez. Expert Opin Investig Drugs 2015
81
17

The landscape of kinase fusions in cancer.
Nicolas Stransky, Ethan Cerami, Stefanie Schalm, Joseph L Kim, Christoph Lengauer. Nat Commun 2014
589
13

Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.
Sun Min Lim, Hye Ryun Kim, Jong-Seok Lee, Ki Hyeong Lee, Yun-Gyoo Lee, Young Joo Min, Eun Kyung Cho, Sung Sook Lee, Bong-Seog Kim, Moon Young Choi,[...]. J Clin Oncol 2017
191
13

Acquired resistance to crizotinib from a mutation in CD74-ROS1.
Mark M Awad, Ryohei Katayama, Michele McTigue, Wei Liu, Ya-Li Deng, Alexei Brooun, Luc Friboulet, Donghui Huang, Matthew D Falk, Sergei Timofeevski,[...]. N Engl J Med 2013
253
13

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.
David S Hong, Steven G DuBois, Shivaani Kummar, Anna F Farago, Catherine M Albert, Kristoffer S Rohrberg, Cornelis M van Tilburg, Ramamoorthy Nagasubramanian, Jordan D Berlin, Noah Federman,[...]. Lancet Oncol 2020
336
13

The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
Luc Friboulet, Nanxin Li, Ryohei Katayama, Christian C Lee, Justin F Gainor, Adam S Crystal, Pierre-Yves Michellys, Mark M Awad, Noriko Yanagitani, Sungjoon Kim,[...]. Cancer Discov 2014
585
13

Entrectinib: First Global Approval.
Zaina T Al-Salama, Susan J Keam. Drugs 2019
54
24

Larotrectinib: First Global Approval.
Lesley J Scott. Drugs 2019
96
13

Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.
Yi-Long Wu, James Chih-Hsin Yang, Dong-Wan Kim, Shun Lu, Jianying Zhou, Takashi Seto, Jin-Ji Yang, Noboru Yamamoto, Myung-Ju Ahn, Toshiaki Takahashi,[...]. J Clin Oncol 2018
165
12

Resistance to TRK inhibition mediated by convergent MAPK pathway activation.
Emiliano Cocco, Alison M Schram, Amanda Kulick, Sandra Misale, Helen H Won, Rona Yaeger, Pedram Razavi, Ryan Ptashkin, Jaclyn F Hechtman, Eneda Toska,[...]. Nat Med 2019
96
12

Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma.
Cristina Tognon, Stevan R Knezevich, David Huntsman, Calvin D Roskelley, Natalya Melnyk, Joan A Mathers, Laurence Becker, Fatima Carneiro, Nicol MacPherson, Doug Horsman,[...]. Cancer Cell 2002
602
12

NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls.
James P Solomon, Irina Linkov, Andrea Rosado, Kerry Mullaney, Ezra Y Rosen, Denise Frosina, Achim A Jungbluth, Ahmet Zehir, Ryma Benayed, Alexander Drilon,[...]. Mod Pathol 2020
216
12

ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research.
C Marchiò, M Scaltriti, M Ladanyi, A J Iafrate, F Bibeau, M Dietel, J F Hechtman, T Troiani, F López-Rios, J-Y Douillard,[...]. Ann Oncol 2019
163
12

Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
Alice T Shaw, Benjamin J Solomon, Rita Chiari, Gregory J Riely, Benjamin Besse, Ross A Soo, Steven Kao, Chia-Chi Lin, Todd M Bauer, Jill S Clancy,[...]. Lancet Oncol 2019
149
12

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.
Klarisa Rikova, Ailan Guo, Qingfu Zeng, Anthony Possemato, Jian Yu, Herbert Haack, Julie Nardone, Kimberly Lee, Cynthia Reeves, Yu Li,[...]. Cell 2007
11


PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.
Helen Y Zou, Qiuhua Li, Lars D Engstrom, Melissa West, Vicky Appleman, Katy A Wong, Michele McTigue, Ya-Li Deng, Wei Liu, Alexei Brooun,[...]. Proc Natl Acad Sci U S A 2015
167
11

The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.
Sen Zhang, Rana Anjum, Rachel Squillace, Sara Nadworny, Tianjun Zhou, Jeff Keats, Yaoyu Ning, Scott D Wardwell, David Miller, Youngchul Song,[...]. Clin Cancer Res 2016
196
11

Targeting TRK family proteins in cancer.
Yekaterina B Khotskaya, Vijaykumar R Holla, Anna F Farago, Kenna R Mills Shaw, Funda Meric-Bernstam, David S Hong. Pharmacol Ther 2017
153
10

Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.
Miho J Fuse, Koutaroh Okada, Tomoko Oh-Hara, Hayato Ogura, Naoya Fujita, Ryohei Katayama. Mol Cancer Ther 2017
58
17

Trk receptors: roles in neuronal signal transduction.
Eric J Huang, Louis F Reichardt. Annu Rev Biochem 2003
10

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.
Justin F Gainor, Leila Dardaei, Satoshi Yoda, Luc Friboulet, Ignaty Leshchiner, Ryohei Katayama, Ibiayi Dagogo-Jack, Shirish Gadgeel, Katherine Schultz, Manrose Singh,[...]. Cancer Discov 2016
665
10


The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma.
Gang Wu, Alexander K Diaz, Barbara S Paugh, Sherri L Rankin, Bensheng Ju, Yongjin Li, Xiaoyan Zhu, Chunxu Qu, Xiang Chen, Junyuan Zhang,[...]. Nat Genet 2014
652
10

CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.
Daniel B Costa, Susumu Kobayashi, Shuchi S Pandya, Wee-Lee Yeo, Zhongzhou Shen, Weiwei Tan, Keith D Wilner. J Clin Oncol 2011
456
10

Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
Francesco Facchinetti, Yohann Loriot, Mei-Shiue Kuo, Linda Mahjoubi, Ludovic Lacroix, David Planchard, Benjamin Besse, Françoise Farace, Nathalie Auger, Jordi Remon,[...]. Clin Cancer Res 2016
91
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.